28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Practical and reliable genotyping procedures with a considerable number of samples are required not only for risk-adapted therapeutic strategies, but also for stratifying patients into future clinical trials for molecular-targeting drugs. Recent advances in mutation testing, including next-generation sequencing, have led to the increased use of formalin-fixed paraffin-embedded tissue. We evaluated gene alteration profiles of cancer-related genes in esophageal cancer patients and correlated them with clinicopathological features, such as smoking status and survival outcomes.

          Methods

          Surgically resected formalin-fixed, paraffin-embedded tissue was collected from 135 consecutive patients with esophageal cancer who underwent esophagectomy. Based on the assessment of DNA quality with a quantitative PCR-based assay, uracil DNA glycosylase pretreatment was performed to ensure quality and accuracy of amplicon-based massively parallel sequencing. Amplicon-based massively parallel sequencing was performed using the Illumina TruSeq® Amplicon Cancer Panel. Gene amplification was detected by quantitative PCR-based assay. Protein expression was determined by automated quantitative fluorescent immunohistochemistry.

          Results

          Data on genetic alterations were available for 126 patients. The median follow-up time was 1570 days. Amplicon-based massively parallel sequencing identified frequent gene alterations in TP53 (66.7%), PIK3CA (13.5%), APC (10.3%), ERBB4 (7.9%), and FBXW7 (7.9%). There was no association between clinicopathological features or prognosis with smoking status. Multivariate analyses revealed that the PIK3CA mutation and clinical T stage were independent favorable prognostic factors (hazard ratio 0.34, 95% confidence interval: 0.12–0.96, p = 0.042). PIK3CA mutations were significantly associated with APC alterations ( p = 0.0007) and BRAF mutations ( p = 0.0090).

          Conclusions

          Our study provided profiles of cancer-related genes in Japanese patients with esophageal cancer by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue, and identified the PIK3CA mutation as a favorable prognosis biomarker.

          Electronic supplementary material

          The online version of this article (10.1186/s12885-018-4733-7) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Performance comparison of benchtop high-throughput sequencing platforms.

          Three benchtop high-throughput sequencing instruments are now available. The 454 GS Junior (Roche), MiSeq (Illumina) and Ion Torrent PGM (Life Technologies) are laser-printer sized and offer modest set-up and running costs. Each instrument can generate data required for a draft bacterial genome sequence in days, making them attractive for identifying and characterizing pathogens in the clinical setting. We compared the performance of these instruments by sequencing an isolate of Escherichia coli O104:H4, which caused an outbreak of food poisoning in Germany in 2011. The MiSeq had the highest throughput per run (1.6 Gb/run, 60 Mb/h) and lowest error rates. The 454 GS Junior generated the longest reads (up to 600 bases) and most contiguous assemblies but had the lowest throughput (70 Mb/run, 9 Mb/h). Run in 100-bp mode, the Ion Torrent PGM had the highest throughput (80–100 Mb/h). Unlike the MiSeq, the Ion Torrent PGM and 454 GS Junior both produced homopolymer-associated indel errors (1.5 and 0.38 errors per 100 bases, respectively).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).

            Patients with esophageal carcinoma receiving postoperative chemotherapy showed superior disease-free survival than those receiving surgery alone in a Japan Clinical Oncology Group trial (JCOG9204). The purpose of this study was to evaluate optimal perioperative timing-that is, before or after surgery-for providing chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Eligible patients with clinical stage II or III, excluding T4, squamous cell carcinoma were randomized to undergo surgery followed (group 1) or preceded (group 2) by chemotherapy consisting of two courses of cisplatin plus 5-fluorouracil. The primary end point was progression-free survival. We randomized 330 patients, with 166 assigned to group 1 and 164 to group 2, between May 2000 and May 2006. The planned interim analysis was conducted after completion of patient accrual. Progression-free survival did not reach the stopping boundary, but overall survival in group 2 was superior to that of group 1 (P = 0.01). Therefore, the Data and Safety Monitoring Committee recommended early publication. Updated analyses showed the 5-year overall survival to be 43% in group 1 and 55% in group 2 (hazard ratio 0.73, 95% confidence interval 0.54-0.99, P = 0.04), where the median follow-up of censored patients was 61.6 months. Concerning operative morbidity, renal dysfunction after surgery in group 2 was slightly higher than in group 1. Preoperative chemotherapy with cisplatin plus 5-fluorouracil can be regarded as standard treatment for patients with stage II/III squamous cell carcinoma.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Genetic landscape of esophageal squamous cell carcinoma.

              Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers. We performed exome sequencing on 113 tumor-normal pairs, yielding a mean of 82 non-silent mutations per tumor, and 8 cell lines. The mutational profile of ESCC closely resembles those of squamous cell carcinomas of other tissues but differs from that of esophageal adenocarcinoma. Genes involved in cell cycle and apoptosis regulation were mutated in 99% of cases by somatic alterations of TP53 (93%), CCND1 (33%), CDKN2A (20%), NFE2L2 (10%) and RB1 (9%). Histone modifier genes were frequently mutated, including KMT2D (also called MLL2; 19%), KMT2C (MLL3; 6%), KDM6A (7%), EP300 (10%) and CREBBP (6%). EP300 mutations were associated with poor survival. The Hippo and Notch pathways were dysregulated by mutations in FAT1, FAT2, FAT3 or FAT4 (27%) or AJUBA (JUB; 7%) and NOTCH1, NOTCH2 or NOTCH3 (22%) or FBXW7 (5%), respectively. These results define the mutational landscape of ESCC and highlight mutations in epigenetic modulators with prognostic and potentially therapeutic implications.
                Bookmark

                Author and article information

                Contributors
                t.yokota@scchr.jp
                m.serizawa@scchr.jp
                ayhosoka@med.miyazaki-u.ac.jp
                k.kusafuka@scchr.jp
                pi0219yb@s.okayama-u.ac.jp
                tsugi@med.u-toyama.ac.jp
                y.tsubosa@scchr.jp
                +81-73-441-0619 , ykoh@wakayama-med.ac.jp
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                16 August 2018
                16 August 2018
                2018
                : 18
                : 826
                Affiliations
                [1 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, ; 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 Japan
                [2 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, ; 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 Japan
                [3 ]ISNI 0000 0001 2171 836X, GRID grid.267346.2, Department of Gastroenterology and Hematology, faculty of Medicine, , University of Toyama, ; Toyama, Japan
                [4 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Pathology Division, Shizuoka Cancer Center, ; 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 Japan
                [5 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Clinical Trial Coordination Office, Shizuoka Cancer Center, ; 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 Japan
                [6 ]ISNI 0000 0004 1774 9501, GRID grid.415797.9, Division of Esophageal Surgery, Shizuoka Cancer Center, ; 1007 Shimonagakubo Nagaizumi-cho Sunto-gun, Shizuoka, 411-8777 Japan
                [7 ]ISNI 0000 0004 1763 1087, GRID grid.412857.d, Third Department of Internal Medicine, , Wakayama Medical University, ; 811-1, Kimiidera, Wakayama-city, Wakayama, 641-0012 Japan
                Article
                4733
                10.1186/s12885-018-4733-7
                6097210
                30115035
                7ac9fe56-9a1a-4d3d-a90c-768118468b73
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 19 June 2018
                : 8 August 2018
                Funding
                Funded by: KAKENHI
                Award ID: 2450136
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Oncology & Radiotherapy
                esophageal cancer,formalin-fixed paraffin-embedded tissue,next-generation sequencing,pik3ca mutation,prognostic factors

                Comments

                Comment on this article